MX2007010185A - Derivados de acido 5-fenil-pentanoico como inhibidores de metaloproteinasa de matriz para el tratamiento de asma y otras enfermedades. - Google Patents
Derivados de acido 5-fenil-pentanoico como inhibidores de metaloproteinasa de matriz para el tratamiento de asma y otras enfermedades.Info
- Publication number
- MX2007010185A MX2007010185A MX2007010185A MX2007010185A MX2007010185A MX 2007010185 A MX2007010185 A MX 2007010185A MX 2007010185 A MX2007010185 A MX 2007010185A MX 2007010185 A MX2007010185 A MX 2007010185A MX 2007010185 A MX2007010185 A MX 2007010185A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- nhc
- aralkyl
- cycloalkyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
Abstract
La presente invencion se relaciona a compuestos que tienen la estructura de la Formula I: en donde n es un numero entero de 1 a 5; R1 es alquilo opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, arilo, heterociclilo, heteroarilo, aralquilo, alcoxi, ariloxi, alqueniloxi o alquiniloxi; R2 es alquenilo, alquinilo, arilo, heterociclilo, heteroarilo, cicloalquilo, NR4R5, -NHC(=Y)R4, -NHC(=Y))NR5RX, -NHC(=0)OR4, -NHSO2R4, C(=Y)NR4R5, C(=0)OR6 [en donde Y es oxigeno o azufre], OR5, -O(C=O)NR4R5, O-acilo, S(O)mR4, -SO2N(R4)2, ciano, amidino o guanidino [en donde R4 es alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heterociclilo, heteroarilo, aralquilo, heteroarilalquilo, heterociclilalquilo o cicloalquilalquilo y m es un numero entero de 0-2; R5 es hidrogeno o R4; RX es R4 o -SO2N(R4)2 y R6 es hidrogeno, alquilo, cicloalquilo, aralquilo, heteroarilalquilo, heterociclilalquilo o cicloalquilalquilo]; R3 es hidrogeno, fluor, alquilo, cicloalquilalquilo o aralquilo; A es OH, OR4, -OC(=O)NR4R5, O-acilo, NH2, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5RX, -NHC(=O)OR4, -NHSO2R4, y a procesos para la sintesis de los mismos. La invencion tambien se relaciona a composiciones farmaceuticas que contienen los compuestos de la presente invencion, y metodos para tratar asma, artritis reumatoide, COPD, rinitis, osteoartritis, artritis psoriatica, psoriasis, fibrosis pulmonar, inflamacion pulmonar, sindrome de angustia respiratoria aguda, perodontitis, esclerosis multiple, gingivitis, aterosclerosis, proliferacion neointimal, que conduce a restenosis y falla del corazon isquemico, ataque apopletico, enfermedades renales, metastasis de tumor, y otros desordenes inflamatorios caracterizados por la sobre-expresion y sobre-activacion de una metaloproteinasa de matriz, usando los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN380DE2005 | 2005-02-22 | ||
PCT/IB2006/000349 WO2006090235A1 (en) | 2005-02-22 | 2006-02-21 | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007010185A true MX2007010185A (es) | 2007-12-06 |
Family
ID=36591260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007010185A MX2007010185A (es) | 2005-02-22 | 2006-02-21 | Derivados de acido 5-fenil-pentanoico como inhibidores de metaloproteinasa de matriz para el tratamiento de asma y otras enfermedades. |
Country Status (33)
Country | Link |
---|---|
US (1) | US8710261B2 (es) |
EP (1) | EP1856063B1 (es) |
JP (1) | JP4994247B2 (es) |
KR (1) | KR101274309B1 (es) |
CN (1) | CN101151255B (es) |
AP (1) | AP2413A (es) |
AT (1) | ATE542804T1 (es) |
AU (1) | AU2006217615B2 (es) |
BR (1) | BRPI0607469A2 (es) |
CA (1) | CA2598518C (es) |
CR (1) | CR9384A (es) |
CY (1) | CY1112795T1 (es) |
DK (1) | DK1856063T3 (es) |
EA (1) | EA013539B1 (es) |
ES (1) | ES2381681T3 (es) |
GE (1) | GEP20094786B (es) |
HK (1) | HK1115379A1 (es) |
HR (1) | HRP20120250T1 (es) |
IL (1) | IL185457A0 (es) |
MA (1) | MA29312B1 (es) |
MX (1) | MX2007010185A (es) |
NI (1) | NI200700220A (es) |
NO (1) | NO20074648L (es) |
NZ (1) | NZ560803A (es) |
PL (1) | PL1856063T3 (es) |
PT (1) | PT1856063E (es) |
RS (2) | RS20070374A (es) |
SI (1) | SI1856063T1 (es) |
SM (1) | SMAP200700038A (es) |
TN (1) | TNSN07320A1 (es) |
UA (1) | UA98292C2 (es) |
WO (1) | WO2006090235A1 (es) |
ZA (1) | ZA200707560B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
PL1856063T3 (pl) | 2005-02-22 | 2012-07-31 | Sun Pharmaceutical Ind Ltd | Pochodne kwasu 5-fenylopentantowego jako inhibitory metaloproteinazy macierzy do leczenia astmy i innych chorób |
EP2474531A3 (en) | 2006-08-22 | 2013-12-04 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
WO2012014114A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
KR20130140688A (ko) | 2010-09-24 | 2013-12-24 | 랜박시 래보러터리스 리미티드 | 기질 메탈로프로테나제 저해제 |
WO2012071516A2 (en) * | 2010-11-23 | 2012-05-31 | Kci Licensing, Inc. | Devices and methods for the diagnosis and treatment of wounds using biomarkers |
EP2556832B1 (en) * | 2011-08-12 | 2017-07-19 | Universitätsklinikum Freiburg | Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease |
GB201322512D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
MX2017007874A (es) | 2014-12-24 | 2018-01-24 | Lg Chemical Ltd | Derivado de biarilo como agonista de gpr120. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5109002A (en) | 1989-09-08 | 1992-04-28 | Du Pont Merck Pharmaceutical Company | Antipsychotic 1-cycloalkylpiperidines |
EP0673247A4 (en) | 1992-12-01 | 1996-05-01 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTS. |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
US5516789A (en) | 1995-04-12 | 1996-05-14 | Abbott Laboratories | Lipoxygenase and cyclooxygenase inhibiting compounds |
AU4159197A (en) | 1996-09-04 | 1998-03-26 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
MY117687A (en) * | 1996-10-31 | 2004-07-31 | Bayer Corp | Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors |
TR199902957T2 (xx) | 1997-06-10 | 2004-12-21 | Unilever N.V. | Bir enzimin etkinli�ini art�rma y�ntemi, a�art�c� bile�imi, deterjan bile�imi ve boya aktar�m�n� �nleme y�ntemi. |
US6037361A (en) * | 1998-03-09 | 2000-03-14 | Warner-Lambert Company | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
AU4229499A (en) * | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
TR200101970T2 (tr) * | 1998-12-30 | 2002-03-21 | Bayer Aktiengesellschaft | Solunum yollarì hastalìklarìnìn tedavisinde matriks metaloproteaz inhibitrleri olarak ikameli 4-biarilbutirik ve 5-biarilpentanoik asit trevlerinin kullanìlmasì |
ITRM20010464A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
US7550474B2 (en) | 2003-04-10 | 2009-06-23 | Johnson & Johnson Pharmaceuticals Research & Development, L.L.C. | Substituted phenyl acetamides and their use as protease inhibitors |
GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
PL1856063T3 (pl) | 2005-02-22 | 2012-07-31 | Sun Pharmaceutical Ind Ltd | Pochodne kwasu 5-fenylopentantowego jako inhibitory metaloproteinazy macierzy do leczenia astmy i innych chorób |
-
2006
- 2006-02-21 PL PL06727254T patent/PL1856063T3/pl unknown
- 2006-02-21 GE GEAP200610276A patent/GEP20094786B/en unknown
- 2006-02-21 BR BRPI0607469-3A patent/BRPI0607469A2/pt not_active IP Right Cessation
- 2006-02-21 RS RSP-2007/0374A patent/RS20070374A/sr unknown
- 2006-02-21 RS RS20120174A patent/RS52232B/en unknown
- 2006-02-21 JP JP2007555726A patent/JP4994247B2/ja not_active Expired - Fee Related
- 2006-02-21 EP EP06727254A patent/EP1856063B1/en active Active
- 2006-02-21 SI SI200631274T patent/SI1856063T1/sl unknown
- 2006-02-21 PT PT06727254T patent/PT1856063E/pt unknown
- 2006-02-21 DK DK06727254.2T patent/DK1856063T3/da active
- 2006-02-21 SM SM200700038T patent/SMAP200700038A/it unknown
- 2006-02-21 ES ES06727254T patent/ES2381681T3/es active Active
- 2006-02-21 CA CA2598518A patent/CA2598518C/en not_active Expired - Fee Related
- 2006-02-21 CN CN2006800101326A patent/CN101151255B/zh not_active Expired - Fee Related
- 2006-02-21 MX MX2007010185A patent/MX2007010185A/es active IP Right Grant
- 2006-02-21 AT AT06727254T patent/ATE542804T1/de active
- 2006-02-21 WO PCT/IB2006/000349 patent/WO2006090235A1/en active Application Filing
- 2006-02-21 KR KR1020077021829A patent/KR101274309B1/ko not_active IP Right Cessation
- 2006-02-21 NZ NZ560803A patent/NZ560803A/en not_active IP Right Cessation
- 2006-02-21 UA UAA200709535A patent/UA98292C2/ru unknown
- 2006-02-21 EA EA200701768A patent/EA013539B1/ru not_active IP Right Cessation
- 2006-02-21 US US11/816,836 patent/US8710261B2/en not_active Expired - Fee Related
- 2006-02-21 AU AU2006217615A patent/AU2006217615B2/en not_active Ceased
- 2006-02-21 AP AP2007004146A patent/AP2413A/xx active
-
2007
- 2007-08-21 TN TNP2007000320A patent/TNSN07320A1/en unknown
- 2007-08-22 NI NI200700220A patent/NI200700220A/es unknown
- 2007-08-22 IL IL185457A patent/IL185457A0/en unknown
- 2007-08-22 MA MA30155A patent/MA29312B1/fr unknown
- 2007-09-03 ZA ZA200707560A patent/ZA200707560B/xx unknown
- 2007-09-12 NO NO20074648A patent/NO20074648L/no not_active Application Discontinuation
- 2007-09-14 CR CR9384A patent/CR9384A/es unknown
-
2008
- 2008-05-15 HK HK08105396.1A patent/HK1115379A1/xx not_active IP Right Cessation
-
2012
- 2012-03-19 HR HR20120250T patent/HRP20120250T1/hr unknown
- 2012-04-04 CY CY20121100336T patent/CY1112795T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007010185A (es) | Derivados de acido 5-fenil-pentanoico como inhibidores de metaloproteinasa de matriz para el tratamiento de asma y otras enfermedades. | |
Rossello et al. | New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) | |
PE20060283A1 (es) | Compuestos inmunosupresores y composiciones | |
FI942381A (fi) | Aryylisubstituoituja heterosyklisiä yhdisteitä | |
JP2008505171A (ja) | 閉塞性気道疾患の処置のための新規ヒダントイン誘導体 | |
DE602005008558D1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen | |
EP2794616B1 (en) | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
TW200635585A (en) | Monocyclic substituted methanones | |
MXPA01007987A (es) | Acido sulfamato hidroxamico inhibidor de metaloproteasa. | |
KR20080046716A (ko) | 4-페닐-6-치환-피리미딘-2-카르보니트릴 유도체 | |
US7589095B2 (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
AR063945A1 (es) | Acidos carboxilicos inhibidores de la metalproteinasa matriz. | |
US6489327B1 (en) | Tryptase inhibitors | |
NO20055694L (no) | Fremgangsmate for fremstilling av (4-hydroksy-6-oksotetrahydropyran-2-yl)acetonitril og derivater derav | |
US20040072871A1 (en) | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | |
EA004858B1 (ru) | Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции | |
MXPA05004365A (es) | Nuevas diamidas del acido pirimidin -4, 6 - dicarboxilico para la inhibicion selectiva de colagenasas. | |
TW200635911A (en) | Sulfanyl substituted phenyl methanones | |
RU2512567C2 (ru) | Фенилалкилпиперазины, модулирующие активность tnf | |
US5374732A (en) | Certain substituted N-fluoropyridiniumsulfonates | |
US20050014817A1 (en) | Fluorothiophene derivatives, process for preparing them and pharmaceutical compositions containing them | |
CN1109025C (zh) | 氨基哌嗪衍生物的新制造法 | |
WO1998030559A1 (en) | Process for the production of tetrazolylbenzopyrans | |
KR20220002871A (ko) | N-아실-[4-[(4-아릴-페닐)설포닐메틸]피페리딘] 화합물 및 이의 치료학적 용도 | |
EP1553077A1 (en) | Process for production of high-purity enamines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |